{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T01:07:15Z","timestamp":1788916035423,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":76,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16430-3","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T07:26:12Z","timestamp":1782372372000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and tolerability of CDK 4\/6 inhibitors in HR-positive HER2-negative de novo metastatic breast cancer patients aged\u2009\u2265\u200970 years"],"prefix":"10.1186","volume":"26","author":[{"given":"Muhammed Mustafa","family":"Atci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7590-6101","authenticated-orcid":false,"given":"Mert","family":"Erciyestepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayhan","family":"Erturk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"issue":"1","key":"16430_CR1","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13045-018-0620-6","volume":"11","author":"A D\u2019Souza","year":"2018","unstructured":"D\u2019Souza A, Spicer D, Lu J. Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer. J Hematol Oncol. 2018;11(1):80.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"16430_CR2","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1093\/annonc\/mdy192","volume":"29","author":"F Cardoso","year":"2018","unstructured":"Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, Andr\u00e9 F, et al. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)\u2020. Ann Oncol. 2018;29(8):1634\u201357.","journal-title":"Ann Oncol"},{"key":"16430_CR3","unstructured":"National Comprehensive Cancer. Network Guidelines \u2013 Breast Cancer Version 4.2025."},{"issue":"6","key":"16430_CR4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s11864-019-0651-4","volume":"20","author":"CG Murphy","year":"2019","unstructured":"Murphy CG. The Role of CDK4\/6 Inhibitors in Breast Cancer. Curr Treat Options Oncol. 2019;20(6):52.","journal-title":"Curr Treat Options Oncol"},{"issue":"3","key":"16430_CR5","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40265-020-01461-2","volume":"81","author":"CL Braal","year":"2021","unstructured":"Braal CL, Jongbloed EM, Wilting SM, Mathijssen RHJ, Koolen SLW, Jager A. Inhibiting CDK4\/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences. Drugs. 2021;81(3):317\u201331.","journal-title":"Drugs"},{"key":"16430_CR6","doi-asserted-by":"publisher","first-page":"175883591879332","DOI":"10.1177\/1758835918793326","volume":"10","author":"M Thill","year":"2018","unstructured":"Thill M, Schmidt M. Management of adverse events during cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitor-based treatment in breast cancer. Ther Adv Med Oncol. 2018;10:1758835918793326.","journal-title":"Ther Adv Med Oncol"},{"key":"16430_CR7","first-page":"101","volume":"14","author":"MC Parati","year":"2022","unstructured":"Parati MC, Pedersini R, Perego G, Reduzzi R, Savio T, Cabiddu M, et al. Ribociclib in the Treatment of Hormone-Receptor Positive\/HER2-Negative Advanced and Early Breast Cancer: Overview of Clinical Data and Patients Selection. Breast Cancer (Dove Med Press). 2022;14:101\u201311.","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"16430_CR8","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"issue":"5","key":"16430_CR9","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383.","journal-title":"J Chronic Dis"},{"key":"16430_CR10","unstructured":"National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services. (NIH publication # 09-7473).Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Published May 29. 2009; Revised Version 4.03 June 14, 2010."},{"issue":"1","key":"16430_CR11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","volume":"16","author":"RS Finn","year":"2015","unstructured":"Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25\u201335.","journal-title":"Lancet Oncol"},{"issue":"20","key":"16430_CR12","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016;375(20):1925\u201336.","journal-title":"N Engl J Med"},{"issue":"10","key":"16430_CR13","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1056\/NEJMoa2114663","volume":"386","author":"GN Hortobagyi","year":"2022","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L, et al. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. N Engl J Med. 2022;386(10):942\u201350.","journal-title":"N Engl J Med"},{"key":"16430_CR14","first-page":"e253687","volume":"25","author":"F Cardoso","year":"2025","unstructured":"Cardoso F, Jacot W, Kuemmel S, Gupta S, Cruz F, Balaraman R, et al. 600- vs 400-mg First-Line Ribociclib in Hormone Receptor-Positive\/ERBB2-Negative Advanced Breast Cancer: The AMALEE Randomized Clinical Trial. JAMA Oncol. 2025;25:e253687.","journal-title":"JAMA Oncol"},{"issue":"23","key":"16430_CR15","doi-asserted-by":"publisher","first-page":"7441","DOI":"10.3390\/jcm13237441","volume":"13","author":"P Fedele","year":"2024","unstructured":"Fedele P, Landriscina M, Moraca L, Gadaleta-Caldarola A, Cusmai A, Giuliani F, et al. Standard Versus Reduced CDK4\/6 Inhibitor Therapy in Elderly Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: An Observational Multicenter Study. J Clin Med. 2024;13(23):7441.","journal-title":"J Clin Med"},{"key":"16430_CR16","doi-asserted-by":"publisher","first-page":"104448","DOI":"10.1016\/j.breast.2025.104448","volume":"81","author":"RM Layman","year":"2025","unstructured":"Layman RM, Liu X, Li B, McRoy L, Brufsky A. Real-world palbociclib dose modifications and clinical outcomes in patients with HR+\/HER2- metastatic breast cancer: A Flatiron Health database analysis. Breast. 2025;81:104448.","journal-title":"Breast"},{"issue":"4","key":"16430_CR17","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.3390\/jcm14041071","volume":"14","author":"AK G\u00fcren","year":"2025","unstructured":"G\u00fcren AK, Guliyev M, Alan \u00d6, \u00c7ad\u0131rci K, Belevi \u0130N, G\u00fclt\u00fcrk \u0130, et al. Evaluation of Dose Reduction Factors and Impact on Progression-Free Survival in Patients Treated with CDK 4\/6 Inhibitors. J Clin Med. 2025;14(4):1071.","journal-title":"J Clin Med"},{"issue":"3","key":"16430_CR18","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s11523-024-01046-z","volume":"19","author":"E Brain","year":"2024","unstructured":"Brain E, Chen C, Simon S, Pasupuleti V, Pfitzer KV, Gelmon KA. Palbociclib in Older Patients with Advanced\/Metastatic Breast Cancer: A Systematic Review. Target Oncol. 2024;19(3):303\u201320.","journal-title":"Target Oncol"},{"key":"16430_CR19","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.breast.2021.10.010","volume":"60","author":"S El Badri","year":"2021","unstructured":"El Badri S, Tahir B, Balachandran K, Bezecny P, Britton F, Davies M, et al. Palbociclib in combination with aromatase inhibitors in patients\u2009\u2265\u200975 years with oestrogen receptor-positive, human epidermal growth factor receptor 2 negative advanced breast cancer: A real-world multicentre UK study. Breast. 2021;60:199\u2013205.","journal-title":"Breast"},{"issue":"14","key":"16430_CR20","doi-asserted-by":"publisher","first-page":"4929","DOI":"10.1002\/cam4.3091","volume":"9","author":"M Takahashi","year":"2020","unstructured":"Takahashi M, Masuda N, Nishimura R, Inoue K, Ohno S, Iwata H, et al. Palbociclib-letrozole as first-line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study. Cancer Med. 2020;9(14):4929\u201340.","journal-title":"Cancer Med"},{"issue":"6","key":"16430_CR21","doi-asserted-by":"publisher","first-page":"101813","DOI":"10.1016\/j.jgo.2024.101813","volume":"15","author":"MS Sedrak","year":"2024","unstructured":"Sedrak MS, Lee MK, Ji J, Satele DV, Freedman RA, Poorvu PD, et al. Palbociclib in adults aged 70 years and older with advanced breast cancer: A phase 2 multicenter trial (Alliance A171601). J Geriatr Oncol. 2024;15(6):101813.","journal-title":"J Geriatr Oncol"},{"key":"16430_CR22","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.breast.2021.11.013","volume":"60","author":"RK Ismail","year":"2021","unstructured":"Ismail RK, van Breeschoten J, Wouters MWJM, van Dartel M, van der Flier S, Reyners AKL, et al. Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer. Breast. 2021;60:263\u201371.","journal-title":"Breast"},{"key":"16430_CR23","doi-asserted-by":"publisher","first-page":"778","DOI":"10.2340\/1651-226X.2025.43226","volume":"64","author":"LS Alan Celik, Dahl","year":"2025","unstructured":"Alan Celik, Dahl LS, Garly R, Glavicic V, Sharma MB, Yammeni S, et al. Impact of age and comorbidities on real-world outcomes in advanced breast cancer patients treated with palbociclib in first line: a nation-wide Danish retrospective study. Acta Oncol. 2025;64:778\u201383.","journal-title":"Acta Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16430-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16430-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16430-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:48:05Z","timestamp":1788914885000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16430-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16430"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16430-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"9 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was reviewed and approved by Saglik Bilimleri University Prof. Dr. Cemil Tascioglu City Hospital Ethics Committee and conducted following the Helsinki Declaration and ethical principles (Approval date and number: October 6, 2025, 355).Written informed consent was taken from all the participants.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1072"}}